Back to top
more

Better trading starts here.

Brokerage Reports

Research for REGN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

2 items in cart

View Cart/Checkout

Regeneron Pharmaceuticals, Inc. [REGN]

Reports for Purchase

Showing records 361 - 380 ( 593 total )

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 361

10/03/2016

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 362

10/03/2016

Company Report

Pages: 2

PDGF Setback,Minor Impact - Buy

Provider: G.RESEARCH, LLC

Analyst: HE J

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 363

09/30/2016

Company Report

Pages: 4

CAPELLA Hits Bump; Eylea Alone Remains Strong Therapy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 364

09/26/2016

Company Report

Pages: 7

First Breakthrough, Now Priority Review for Dupilumab

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 365

09/26/2016

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 366

09/21/2016

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 367

09/21/2016

Company Report

Pages: 2

Teva Deal on NGF - Buy

Provider: G.RESEARCH, LLC

Analyst: HE J

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 368

09/20/2016

Company Report

Pages: 7

Fasinumab Monetized; It''s Been a Long Road for the Class; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 369

09/12/2016

Company Report

Pages: 9

Price: 24.95

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 370

08/09/2016

Company Report

Pages: 8

Price: 24.95

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 371

08/08/2016

Company Report

Pages: 8

Price: 24.95

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 372

08/05/2016

Company Report

Pages: 2

Guidance - Buy

Provider: G.RESEARCH, LLC

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 373

08/05/2016

Daily Note

Pages: 7

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 374

08/04/2016

Company Report

Pages: 7

2Q16 Results; Blocking and Tackling on Revenue Growth and Pipeline

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 375

07/04/2016

Company Report

Pages: 7

Price: 24.95

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 376

06/06/2016

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 377

06/06/2016

Company Report

Pages: 8

Dupilumab Continues to Shine Ahead of 3Q16 BLA Filing

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 378

06/01/2016

Company Report

Pages: 7

Price: 24.95

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 379

05/10/2016

Company Report

Pages: 7

Price: 24.95

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 380

05/06/2016

Company Report

Pages: 7

1Q16 Results; The Juggernaut Pushes Forward; Reiterate Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party